‘Text/HTML’ of page ‘EAY191-N4 (ComboMATCH): RAS Pathway Mutation in Ovarian and Endometrial Cancers’
Frequently Asked Questions Below, you can find FAQs about clinical research and this particular clinical trial.
Read MoreContent Block Tag: EAY191-N4 (ComboMATCH): RAS Pathway Mutation in Ovarian and Endometrial Cancers
‘Text/HTML’ of page ‘EAY191-N4 (ComboMATCH): RAS Pathway Mutation in Ovarian and Endometrial Cancers’
Am I eligible for this study? If you are over the age of 18 and have recurrent or persistent ovarian or endometrial cancer with a RAS pathway mutation, you may be able to participate. Your healthcare team is the best source for information about your treatment options, including cancer clinical trials. Be sure to take […]
Read More‘Text/HTML’ of page ‘EAY191-N4 (ComboMATCH): RAS Pathway Mutation in Ovarian and Endometrial Cancers’
About This Study EAY191-N4 is part of the ComboMATCH precision medicine initiative for people that have recurrent or persistent ovarian and endometrial cancers with a RAS pathway mutation. The ComboMATCH registration trial studies show how well treatment that is directed by genetic testing works in treating patients with solid tumors that have spread to nearby […]
Read More‘Text/HTML’ of page ‘EAY191-N4 (ComboMATCH): RAS Pathway Mutation in Ovarian and Endometrial Cancers’
Clinical Studies FAQ
Read More‘Text/HTML’ of page ‘EAY191-N4 (ComboMATCH): RAS Pathway Mutation in Ovarian and Endometrial Cancers’
The EAY191-N4 Study FAQ
Read More